Health

STAT+: Pharmalittle: We’re reading about WHO obesity guidelines for kids, DOJ targeting pharma, and more

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 07/10/2026, 21:21:26 UTC.

Briefings

The World Health Organization released its first guidelines addressing the sharp rise in obesity among children and adolescents, noting that in 2024, 170 million children aged 5-19 years were living with obesity, with prevalence quadrupling since 1990. The WHO does not recommend pharmacological treatment or weight loss devices for children under 10, while approved drugs for adolescents may be considered only after failed lifestyle programs. Caribou Biosciences is shutting down due to funding issues for a late-stage clinical trial of its CAR-T therapy for lymphoma, following a successful Phase 3 trial design with the FDA.

Key points

• The World Health Organization released its first guidelines addressing the sharp rise in obesity among children and adolescents, noting that in 2024, 170 million children aged 5-19 years were living with obesity, with prevalence quadrupling since 1990.
• Caribou Biosciences is shutting down due to funding issues for a late-stage clinical trial of its CAR-T therapy for lymphoma, following a successful Phase 3 trial design with the FDA.

Context and limitations

Coverage is limited to WHO obesity guidelines and Caribou Biosciences' clinical trial closure; data on obesity prevalence is from 2024, and specific drug approval statuses for adolescents are conditional on lifestyle program failure.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 08/10/2026, 11:05:37 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeihzrl2caemafsqmhwh5q3md4tbda2sq66tjcso6jchsvwrdexiipi